Clinical Trial: A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

U.S., Feb. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07392190) titled 'A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin' on Jan. 30.

Brief Summary: The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy.

Participation in the study will last about 80 weeks.

Study Start Date: March, 2026

Study Type: INTERVENTIONAL

Condition: Overweight Obesity

Intervention: DRUG: Eloralintide

Administered SC

DRUG: Placebo

Administered SC

Recruitment Status: NOT_YET_R...